A Phase I Open-label Study to Investigate the Mass Balance and Biotransformation of a Single Oral 160 mg (100 microCi) Dose of 14C-MDV3100 (ASP9785) in Healthy Male Subjects

Trial Profile

A Phase I Open-label Study to Investigate the Mass Balance and Biotransformation of a Single Oral 160 mg (100 microCi) Dose of 14C-MDV3100 (ASP9785) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Breast cancer; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 06 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top